Cargando…
Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022
This study intends to evaluate the development, importance, pre-clinical and clinical study evaluation of stem cell therapy for the treatment of cardiovascular disease. Cardiovascular disease is one of the main causes of fatality in the whole world. Though there are great progressions in the pharmac...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563042/ https://www.ncbi.nlm.nih.gov/pubmed/36249945 http://dx.doi.org/10.1016/j.jsps.2022.06.017 |
_version_ | 1784808313317228544 |
---|---|
author | Mahmud, Shabnur Alam, Safaet Emon, Nazim Uddin Boby, Umme Habiba Kamruzzaman Ahmed, Firoj Monjur-Al-Hossain, A.S.M. Tahamina, Afroza Rudra, Sajib Ajrin, Marzina |
author_facet | Mahmud, Shabnur Alam, Safaet Emon, Nazim Uddin Boby, Umme Habiba Kamruzzaman Ahmed, Firoj Monjur-Al-Hossain, A.S.M. Tahamina, Afroza Rudra, Sajib Ajrin, Marzina |
author_sort | Mahmud, Shabnur |
collection | PubMed |
description | This study intends to evaluate the development, importance, pre-clinical and clinical study evaluation of stem cell therapy for the treatment of cardiovascular disease. Cardiovascular disease is one of the main causes of fatality in the whole world. Though there are great progressions in the pharmacological and other interventional treatment options, heart diseases remain a common disorder that causes long-term warnings. Recent accession promotes the symptoms and slows down the adverse effects regarding cardiac remodelling. But they cannot locate the problems of immutable loss of cardiac tissues. In this case, stem cell treatment holds a promising challenge. Stem cells are the cells that are capable of differentiating into many cells according to their needs. So, it is assumed that these cells can distinguish into many cells and if these cells can be individualized into cardiac cells then they can be used to replace the damaged tissues of the heart. There is some abridgment in this therapy, none the less stem cell therapy remains a hopeful destination in the treatment of heart disease. |
format | Online Article Text |
id | pubmed-9563042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-95630422022-10-15 Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022 Mahmud, Shabnur Alam, Safaet Emon, Nazim Uddin Boby, Umme Habiba Kamruzzaman Ahmed, Firoj Monjur-Al-Hossain, A.S.M. Tahamina, Afroza Rudra, Sajib Ajrin, Marzina Saudi Pharm J Review This study intends to evaluate the development, importance, pre-clinical and clinical study evaluation of stem cell therapy for the treatment of cardiovascular disease. Cardiovascular disease is one of the main causes of fatality in the whole world. Though there are great progressions in the pharmacological and other interventional treatment options, heart diseases remain a common disorder that causes long-term warnings. Recent accession promotes the symptoms and slows down the adverse effects regarding cardiac remodelling. But they cannot locate the problems of immutable loss of cardiac tissues. In this case, stem cell treatment holds a promising challenge. Stem cells are the cells that are capable of differentiating into many cells according to their needs. So, it is assumed that these cells can distinguish into many cells and if these cells can be individualized into cardiac cells then they can be used to replace the damaged tissues of the heart. There is some abridgment in this therapy, none the less stem cell therapy remains a hopeful destination in the treatment of heart disease. Elsevier 2022-09 2022-06-22 /pmc/articles/PMC9563042/ /pubmed/36249945 http://dx.doi.org/10.1016/j.jsps.2022.06.017 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mahmud, Shabnur Alam, Safaet Emon, Nazim Uddin Boby, Umme Habiba Kamruzzaman Ahmed, Firoj Monjur-Al-Hossain, A.S.M. Tahamina, Afroza Rudra, Sajib Ajrin, Marzina Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022 |
title | Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022 |
title_full | Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022 |
title_fullStr | Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022 |
title_full_unstemmed | Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022 |
title_short | Opportunities and challenges in stem cell therapy in cardiovascular diseases: Position standing in 2022 |
title_sort | opportunities and challenges in stem cell therapy in cardiovascular diseases: position standing in 2022 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563042/ https://www.ncbi.nlm.nih.gov/pubmed/36249945 http://dx.doi.org/10.1016/j.jsps.2022.06.017 |
work_keys_str_mv | AT mahmudshabnur opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022 AT alamsafaet opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022 AT emonnazimuddin opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022 AT bobyummehabiba opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022 AT kamruzzaman opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022 AT ahmedfiroj opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022 AT monjuralhossainasm opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022 AT tahaminaafroza opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022 AT rudrasajib opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022 AT ajrinmarzina opportunitiesandchallengesinstemcelltherapyincardiovasculardiseasespositionstandingin2022 |